Abstract
A series of 1,3,6-triphenylpyrazolo[3,4-b]pyridin-4-one derivatives was designed, synthesized and evaluated for cytotoxic activity in A375 human melanoma and human erythroleukemia (HEL) cells. The new pyrazolopyridones displayed comparable activities to the antitumor compound etoposide. The inhibitory effect of compounds 17, 18, 27 and 32 against topoisomerase II-mediated cleavage activities was measured finding good correlation with the results obtained from MTS assay. Docking studies into bacterial topoisomerase II (DNA Gyrase), topoisomerase IIα and topoisomerase IIβ binding sites in the DNA binding interface were performed.
Keywords: Pyrazolo[3, 4-b]pyridine, etoposide, topoisomerase, docking studies.
Graphical Abstract
Medicinal Chemistry
Title:Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors
Volume: 11 Issue: 4
Author(s): Mojgan Aghazadeh Tabrizi, Pier Giovanni Baraldi, Stefania Baraldi, Filippo Prencipe, Delia Preti, Giulia Saponaro, Romeo Romagnoli, Stefania Gessi, Stefania Merighi, Angela Stefanelli, Debora Fazzi, Pier Andrea Borea, Rodolfo Couto Maia, Nelilma C. Romeiro, Carlos A. M. Fraga and Eliezer J. Barreiro
Affiliation:
Keywords: Pyrazolo[3, 4-b]pyridine, etoposide, topoisomerase, docking studies.
Abstract: A series of 1,3,6-triphenylpyrazolo[3,4-b]pyridin-4-one derivatives was designed, synthesized and evaluated for cytotoxic activity in A375 human melanoma and human erythroleukemia (HEL) cells. The new pyrazolopyridones displayed comparable activities to the antitumor compound etoposide. The inhibitory effect of compounds 17, 18, 27 and 32 against topoisomerase II-mediated cleavage activities was measured finding good correlation with the results obtained from MTS assay. Docking studies into bacterial topoisomerase II (DNA Gyrase), topoisomerase IIα and topoisomerase IIβ binding sites in the DNA binding interface were performed.
Export Options
About this article
Cite this article as:
Tabrizi Aghazadeh Mojgan, Baraldi Giovanni Pier, Baraldi Stefania, Prencipe Filippo, Preti Delia, Saponaro Giulia, Romagnoli Romeo, Gessi Stefania, Merighi Stefania, Stefanelli Angela, Fazzi Debora, Borea Andrea Pier, Maia Couto Rodolfo, Romeiro C. Nelilma, Fraga A. M. Carlos and Barreiro J. Eliezer, Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors, Medicinal Chemistry 2015; 11 (4) . https://dx.doi.org/10.2174/1573406411666141210141317
DOI https://dx.doi.org/10.2174/1573406411666141210141317 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Current Drug Safety Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design The IL-7/IL-7 Receptor Axis: Understanding its Central Role in T-Cell Homeostasis and the Challenges Facing its Utilization as a Novel Therapy
Current Drug Targets Streamlined In Vivo Selection and Screening of Human Prostate Carcinoma Avid Phage Particles for Development of Peptide Based In Vivo Tumor Imaging Agents
Combinatorial Chemistry & High Throughput Screening One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Meet Our Editorial Board Member
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design Ribosome Inactivating Proteins (RIPs) from Momordica charantia for Anti Viral Therapy
Current Molecular Medicine Molecular Mechanisms of Pancreatic Cancer Dissemination: The Role of the Chemokine System
Current Pharmaceutical Design Ansamycin Inhibitors of Hsp90: Natures Prototype for Anti-Chaperone Therapy
Current Topics in Medicinal Chemistry The Impact of Cell-free Plasma DNA on Metastatic and Nonmetastatic Prostate Cancer
Current Molecular Medicine Synthesis and characterization of a new retinoic acid ECPIRM as potential chemotherapeutic agent for human cutaneous squamous carcinoma
Anti-Cancer Agents in Medicinal Chemistry Cationic Liposomes as Non-viral Vector for RNA Delivery in Cancer Immunotherapy
Recent Patents on Drug Delivery & Formulation Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Induction of Apoptotic Cell Death in Tumor Cells by S100A8/A9 Released from Inflammatory Cells Upon Cellular Activation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Galectin-1 as a Potential Therapeutic Agent for Amyotrophic Lateral Sclerosis
Current Drug Targets Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology